Antibiotic research and development: business as usual?
Author:
Harbarth S.1, Theuretzbacher U.2, Hackett J.3, Adriaenssens Niels, Anderson James, Antonisse Ad, Årdal Christine, Baillon-Plot Nathalie, Baraldi Enrico, Bettiol Esther, Bhatti Taimur, Bradshaw David, Brown Nicholas, Carmeli Yehuda, Cars Otto, Charbonneau Claudie, Cheng Sue, Ciabuschi Francesco, Cirino Joseph, Clift Charles, Colson Abby, Dane Aaron, De-Lima Natalie, Dooa Mindy, Drabik Dusan, Eisenstein Barry, Farquhar Ronald, Fidan Dogan, Findlay David, Galli Frederic, Gilchrist Kim, Gilman Steve, Goeschl Timo, Goodall Jonathan, Goossens Herman, Gouglas Dimitrios, Guise Tracey, Gyssens Inge, Hallerbäck Peter, Heymann David, Hoffman Steven, Howell Jenny, Hulscher Marlies, Hunt Timothy, Huttner Benedikt, Jantarada Fabricio, Jaquest Dominique, Joly Florence, Ka Lum, Karas Andreas, Knirsch Charles, Kullberg Bart-Jan, Laxminarayan Ramanan, Le Maréchal Marion, Legros Stéphane, Lilliott Nicky, Lindgren Eva, Longshaw Chris, Mahoney Nicole, Mastrangelo Dana, McDonald John, McKeever Steve, Mepham Tim, Milanic Romina, Monnier Annelie, Morel Chantal, Morton Alec, Mossialos Elias, Nolet Brigitte, Outterson Kevin, Payne David, Piddock Laura, Plahte Jens, Potter Danielle, Pulcini Céline, Rex John, Ross Emma, Rottingen John-Arne, Ryan Kellie, Ryan James, Salimi Tehseen, Schouten Jeroen, Schultz Suzanne, So Antony, Spiesser Julie, Stålhammar Nils-Olov, Stanic Mirji, Tacconelli Evelina, Temkin Liz, Trick Donald, Vink Patrick, Vlahovic-Palcevski Vera, Watt Maureen, Wells Marc, Wesseler Justus, White Alex, Wood Susan, Zanichelli Veronica, Zorzet Anna,
Affiliation:
1. 1 Infection Control Program and Division of Infectious Diseases, University of Geneva Hospitals and Medical Faculty, Geneva, Switzerland 2. 2 Center for Anti-Infective Agents, Vienna, Austria 3. 3 AstraZeneca Research & Development, Gaithersburg, MD, USA
Abstract
Abstract
The global burden of antibiotic resistance is tremendous and, without new anti-infective strategies, will continue to increase in the coming decades. Despite the growing need for new antibiotics, few pharmaceutical companies today retain active antibacterial drug discovery programmes. One reason is that it is scientifically challenging to discover new antibiotics that are active against the antibiotic-resistant bacteria of current clinical concern. However, the main hurdle is diminishing economic incentives. Increased global calls to minimize the overuse of antibiotics, the cost of meeting regulatory requirements and the low prices of currently marketed antibiotics are strong deterrents to antibacterial drug development programmes. New economic models that create incentives for the discovery of new antibiotics and yet reconcile these incentives with responsible antibiotic use are long overdue. DRIVE-AB is a €9.4 million public–private consortium, funded by the EU Innovative Medicines Initiative, that aims to define a standard for the responsible use of antibiotics and to develop, test and recommend new economic models to incentivize investment in producing new anti-infective agents.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|